NBW Capital LLC Acquires 915 Shares of Danaher Co. (NYSE:DHR)

NBW Capital LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 3.8% in the first quarter, Holdings Channel reports. The institutional investor owned 24,779 shares of the conglomerate’s stock after acquiring an additional 915 shares during the quarter. NBW Capital LLC’s holdings in Danaher were worth $6,188,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Mosaic Family Wealth Partners LLC increased its holdings in Danaher by 75.8% during the 1st quarter. Mosaic Family Wealth Partners LLC now owns 2,087 shares of the conglomerate’s stock worth $521,000 after acquiring an additional 900 shares during the period. EverSource Wealth Advisors LLC grew its position in Danaher by 5.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,366 shares of the conglomerate’s stock worth $337,000 after buying an additional 69 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in Danaher by 4.3% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 710,636 shares of the conglomerate’s stock worth $176,325,000 after acquiring an additional 29,081 shares during the last quarter. Cambridge Trust Co. raised its holdings in shares of Danaher by 17.5% in the 1st quarter. Cambridge Trust Co. now owns 87,500 shares of the conglomerate’s stock valued at $21,850,000 after acquiring an additional 13,062 shares in the last quarter. Finally, Soltis Investment Advisors LLC bought a new stake in shares of Danaher during the 1st quarter valued at about $290,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on DHR. Stifel Nicolaus lifted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Royal Bank of Canada increased their target price on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group increased their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. SVB Leerink upped their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Citigroup increased their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $276.88.

Danaher Trading Down 1.4 %

NYSE DHR traded down $4.01 during trading on Friday, hitting $276.75. The company had a trading volume of 3,108,808 shares, compared to its average volume of 3,183,765. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a market cap of $199.87 billion, a price-to-earnings ratio of 46.91, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. The company’s fifty day moving average is $256.29 and its 200-day moving average is $250.94. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm posted $2.05 earnings per share. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, sell-side analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 26th. Shareholders of record on Friday, June 28th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date was Friday, June 28th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity

In other news, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $7,441,441.35. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Danaher news, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now owns 41,149 shares in the company, valued at approximately $11,501,145.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The disclosure for this sale can be found here. Insiders sold 113,174 shares of company stock worth $29,775,644 over the last three months. 11.10% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.